Panbela Therapeutics, Inc. (PBLA) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 22 transactions totaling $51.7K, demonstrating a bearish sentiment with -$51.7K in net insider flow. The most recent transaction on Nov 8, 2023 involved a sale of 72,874 shares valued at $51.7K.
No significant insider buying has been recorded for PBLA in the recent period.
No significant insider selling has been recorded for PBLA in the recent period.
Based on recent SEC filings, insider sentiment for PBLA is bearish with an Insider Alignment Score of 0/100 and a net flow of -$51.7K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Panbela Therapeutics, Inc. (PBLA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading PBLA stock, having executed 22 transactions in the past 90 days. The most active insider is Sachs &. Co. Llc Goldman (Executive), who has made 1 transactions totaling $51.7K.
Get notified when executives and directors at PBLA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 8, 2023 | &. Co. Llc Goldman Sachs | Executive | Sale | 72,874 | $0.71 | $51.7K | |
| Sep 12, 2023 | E. Jacob Jeffrey | Executive | Gift | 275 | $N/A | $0 | |
| Jan 30, 2023 | Horvath Susan | Executive | Purchase | 4,444 | $N/A | $0 | |
| Jan 30, 2023 | K. Simpson Jennifer | Executive | Purchase | 4,444 | $N/A | $0 | |
| Oct 4, 2022 | E. Jacob Jeffrey | Executive | Purchase | 33,000 | $N/A | $0 | |
| Oct 4, 2022 | Robert Schemel Donald | Executive | Purchase | 200,000 | $N/A | $0 | |
| Oct 4, 2022 | T. Cullen Michael | Executive | Purchase | 165,000 | $N/A | $0 | |
| May 25, 2021 | T. Cullen Michael | Executive | Award | 4,316 | $N/A | $0 | |
| May 25, 2021 | W. Schaffer Paul | Executive | Award | 4,316 | $N/A | $0 | |
| May 25, 2021 | S. Mathiesen Jeffrey | Executive | Award | 4,316 | $N/A | $0 | |
| May 25, 2021 | Robert Schemel Donald | Executive | Award | 4,316 | $N/A | $0 | |
| May 25, 2021 | Fratamico Arthur | Executive | Award | 4,316 | $N/A | $0 | |
| Apr 29, 2021 | Gagnon Suzanne | Executive | Gift | 1,000 | $N/A | $0 | |
| Jan 6, 2021 | Gagnon Suzanne | Executive | Gift | 7,142 | $N/A | $0 | |
| Jan 6, 2021 | Gagnon Suzanne | Executive | Gift | 3,284 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 1 | $51.7K | 100.0% |
Gift(G) | 7 | $0 | 0.0% |
Purchase(P) | 5 | $0 | 0.0% |
Award(A) | 9 | $0 | 0.0% |
Insider selling pressure at Panbela Therapeutics, Inc. has increased, with 10 insiders executing 22 transactions across all time. Total sales of $51.7K significantly outpace purchases of $0, resulting in a net outflow of $51.7K. This selling activity appears largely discretionary, which may warrant closer attention from investors.